
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited EBITDA 2011-2026 | BNR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -749 M | -379 M | -138 M | -137 M | -99.6 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -99.6 M | -749 M | -300 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.85 | -3.72 % | $ 92.5 K | ||
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.67 B | $ 118.6 | 0.4 % | $ 36.1 B | ||
|
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | ||
|
Celcuity
CELC
|
-113 M | $ 107.62 | -0.63 % | $ 4.25 B | ||
|
Fulgent Genetics
FLGT
|
-49 M | $ 13.82 | -2.68 % | $ 418 M | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
24.7 M | $ 27.55 | -1.59 % | $ 765 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
428 M | $ 175.77 | -1.61 % | $ 8.71 B | ||
|
ICON Public Limited Company
ICLR
|
1.59 B | $ 108.44 | 0.16 % | $ 8.94 B | ||
|
IDEXX Laboratories
IDXX
|
1.51 B | $ 635.29 | -0.22 % | $ 51.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 283.19 | -1.07 % | $ 23.6 B | ||
|
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
381 M | $ 79.15 | 3.74 % | $ 5.34 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 315.61 | -0.56 % | $ 27.1 B | ||
|
Biodesix
BDSX
|
-28.7 M | $ 15.5 | -1.59 % | $ 2.01 B | ||
|
Myriad Genetics
MYGN
|
-334 M | $ 5.26 | 4.89 % | $ 487 M | ||
|
NeoGenomics
NEO
|
-79.8 M | $ 9.53 | 0.26 % | $ 1.22 B | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
National Research Corporation
NRC
|
40.2 M | $ 13.37 | -3.47 % | $ 328 M | ||
|
Natera
NTRA
|
-524 M | $ 206.39 | 3.11 % | $ 20.3 B | ||
|
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
-90 M | $ 1.12 | -1.78 % | $ 1.42 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 208.28 | -0.95 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
5.44 B | $ 204.04 | -0.9 % | $ 145 B | ||
|
Organovo Holdings
ONVO
|
-12.4 M | - | -2.3 % | $ 19.4 M | ||
|
OPKO Health
OPK
|
-53.9 M | $ 1.22 | -2.02 % | $ 847 M | ||
|
Pacific Biosciences of California
PACB
|
-541 M | $ 1.51 | -7.1 % | $ 453 M | ||
|
Exact Sciences Corporation
EXAS
|
-81.4 M | $ 103.38 | 0.02 % | $ 19.5 B | ||
|
Bioventus
BVS
|
-24.4 M | $ 8.8 | 0.34 % | $ 551 M | ||
|
DarioHealth Corp.
DRIO
|
-55.7 M | $ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
1.16 B | $ 73.0 | -1.06 % | $ 28.5 B | ||
|
PerkinElmer
PKI
|
762 M | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
-1.22 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
-6.4 M | $ 24.78 | 0.38 % | $ 32.2 M | ||
|
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B | ||
|
Quotient Limited
QTNT
|
-73.9 M | - | -11.32 % | $ 1.1 M | ||
|
Illumina
ILMN
|
-479 M | $ 129.9 | -2.25 % | $ 20.7 B | ||
|
Renalytix AI plc
RNLX
|
-29.2 M | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
-25.9 M | $ 0.2 | -0.74 % | $ 19.2 M |